On Monday, Novavax said its COVID-19 vaccine was more than 90 percent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial.
The study of nearly 30,000 volunteers in the United States and Mexico puts Novavax on track to file for emergency authorization in the United States and elsewhere in the third quarter of 2021, the company said.
The protein-based vaccine was more than 93 percent effective against the more easily transmissible predominant coronavirus variants that have caused concern among scientists and public health officials, Novavax said.
Please select this link to read the complete article from Reuters.